Franklin Resources Inc. Has $10.67 Million Stock Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Franklin Resources Inc. cut its stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 62.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 441,332 shares of the company's stock after selling 735,863 shares during the period. Franklin Resources Inc. owned 0.20% of Hims & Hers Health worth $10,671,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Crewe Advisors LLC acquired a new stake in Hims & Hers Health in the fourth quarter worth about $28,000. Raleigh Capital Management Inc. boosted its holdings in shares of Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after acquiring an additional 1,100 shares in the last quarter. Blume Capital Management Inc. increased its stake in shares of Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after acquiring an additional 600 shares during the period. Smartleaf Asset Management LLC raised its holdings in Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after purchasing an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC bought a new position in Hims & Hers Health during the 4th quarter valued at $38,000. 63.52% of the stock is currently owned by institutional investors.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 54,153 shares of the business's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $29.90, for a total value of $1,619,174.70. Following the transaction, the insider now owns 165,650 shares of the company's stock, valued at approximately $4,952,935. The trade was a 24.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Melissa Baird sold 33,337 shares of the firm's stock in a transaction on Wednesday, April 9th. The shares were sold at an average price of $27.32, for a total value of $910,766.84. Following the completion of the sale, the chief operating officer now owns 805,083 shares of the company's stock, valued at approximately $21,994,867.56. This trade represents a 3.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 824,303 shares of company stock valued at $31,376,661 over the last quarter. 17.71% of the stock is owned by company insiders.

Remove Ads

Analyst Ratings Changes

Several equities research analysts have commented on HIMS shares. Needham & Company LLC boosted their price target on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a "buy" rating in a research report on Tuesday, February 25th. Leerink Partners increased their price objective on Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research report on Tuesday, February 25th. Citigroup reaffirmed a "sell" rating on shares of Hims & Hers Health in a research report on Wednesday, April 2nd. Truist Financial dropped their price target on Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a research note on Thursday. Finally, Bank of America lifted their target price on shares of Hims & Hers Health from $21.00 to $22.00 and gave the stock an "underperform" rating in a research report on Tuesday, March 18th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, Hims & Hers Health has an average rating of "Hold" and an average target price of $38.25.

Hims & Hers Health Trading Up 1.2 %

Hims & Hers Health stock traded up $0.33 on Monday, reaching $27.56. 3,746,006 shares of the stock were exchanged, compared to its average volume of 15,104,026. Hims & Hers Health, Inc. has a twelve month low of $11.20 and a twelve month high of $72.98. The stock has a market cap of $6.12 billion, a PE ratio of 62.63 and a beta of 1.65. The firm has a fifty day moving average price of $38.75 and a two-hundred day moving average price of $30.46.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. The business had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.